Osimertinib: A third-generation tyrosine kinase inhibitor for treatment of epidermal growth factor receptor-mutated non-small cell lung cancer with the acquired Thr790Met mutation

Journal of Oncology Pharmacy Practice, Ahead of Print.


from Cancer via ola Kala on Inoreader http://ift.tt/2rcGh2C
via IFTTT